Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall
Title and authors | Publication | Year |
---|---|---|
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
VI Zannis, A Chroni, M Krieger |
Journal of Molecular Medicine | 2006 |
Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
FC Luft |
Journal of Molecular Medicine | 2006 |
The potential for CETP inhibition to reduce cardiovascular disease risk
B Ansell, FD Hobbs |
Current Medical Research and Opinion | 2006 |
High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease
M Gomaraschi, L Calabresi, G Franceschini |
Expert Opinion on Therapeutic Targets | 2006 |
Plasma lipid transfer proteins
XC Jiang, HW Zhou |
Current Opinion in Lipidology | 2006 |
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
PJ Barter, JJ Kastelein |
Journal of the American College of Cardiology | 2006 |
Aging and high-density lipoprotein metabolism
Y Arai, N Hirose |
Aging Health | 2006 |
Cholesteryl ester transfer protein gene mutations in Brazilian hyperalphalipoproteinemia
DB Kaplan, R Schreiber, HC Oliveira, LM Harada, RT Nakamura, HP Pinheiro, J Tentor, ML Cruz, EC Faria |
Clinical Genetics | 2006 |
Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol
H Mabuchi, A Inazu |
Future Lipidology | 2006 |
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
JM Lee, RP Choudhury |
Heart (British Cardiac Society) | 2006 |
HDL: The ‘new’ target of cardiovascular medicine
T Sampietro, F Bigazzi, BD Pino, M Puntoni, A Bionda |
International Journal of Cardiology | 2006 |
I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people
C Vergani, T Lucchi, M Caloni, I Ceconi, C Calabresi, S Scurati, B Arosio |
Archives of Gerontology and Geriatrics | 2006 |
Recent developments in the treatment of atherosclerosis: Review article
PS Brahmkshatriya, MH Jani, MT Chhabria |
Journal of Enzyme Inhibition and Medicinal Chemistry | 2006 |
High-density lipoprotein: is it always atheroprotective?
Benjamin J Ansell, Gregg C Fonarow, Alan M Fogelman |
Current Atherosclerosis Reports | 2006 |
High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation
PA McPherson, IS Young, B McKibben, J McEneny |
Journal of lipid research | 2006 |
Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice
AC Casquero, JA Berti, AG Salerno, EJ Bighetti, PM Cazita, DF Ketelhuth, M Gidlund, HC Oliveira |
Journal of lipid research | 2006 |
Familial Dyslipidaemias: An Overview of Genetics, Pathophysiology and Management
SB Hachem, AD Mooradian |
Drugs | 2006 |